Which is the Safest Strategy to Treat Moderate to Severe IBD?
|
|
|
- Denis Booker
- 5 years ago
- Views:
Transcription
1 Which is the Safest Strategy to Treat Moderate to Severe IBD? David G. Binion, M.D. Co-Director, Inflammatory Bowel Disease Center Director, Translational Inflammatory Bowel Disease Research Visiting Professor of Medicine Division of Gastroenterology, Hepatology and Nutrition University of Pittsburgh School of Medicine UPMC Presbyterian Hospital Pittsburgh, PA, USA
2 Disclosure Grant Support National Institutes of Health Crohn s and Colitis Foundation of America Centocor Elan Biogen Proctor and Gamble Honoraria/consulting Centocor, Prometheus Laboratories, Abbott laboratories, UCB Pharma, Elan Biogen Off label discussion of Drugs
3 What is the Most Effective Strategy for Moderate to Severe IBD? Outline Heterogeneity of IBD subgroups Confounding issues infections, adverse drug reactions and strictures Personalized medicine for specific levels of disease severity
4 IBD 2010 More effective drugs are available for IBD at this time than ever before IBD patients are still being admitted to the hospital higher numbers than ever before Why? annual hospitalization rates for IBD (Nationwide inpatient sample) - Crohn s disease rose from 9.3 to 17.1 / 100,000 (p=0.0002) - UC rose from 8.2 to 12.4 / 100,000 (p=0.06) What is underlying severe/refractory IBD and this increase in hospitalizations? Bewtra M, et al. Clin Gastroenterol Hepatol. 2007;5:
5 Patients With UC (N=1161) UC: Disease Severity at Presentation 100% 80% Fulminant Disease (9%) 60% 40% Moderate-to-High Activity (71%) 20% 0% Low Activity (20%) Disease Activity Copenhagen County, Denmark, 1962 to 1987 Langholz EP et al. Scand J Gastroenterol. 1991;26:1247
6 Colectomy Rate (%) UC Natural History Colectomy Rate Over Time 40% 30% 31% 20% 23% 10% 10% 0% Hendriksen C, Kreiner S, Binder V. Gut 1985;26:
7 C. difficile: Changing Spectrum of Clinical Disease Discharges per 100,000 population In the past: C. difficile linked to antibiotic use. Most cases treated successfully with metronidazole Doubling of C. difficile associated disease between ,000 cases in US annually Any diagnosis Primary 15,000 deaths in US annually 50 Diminished therapeutic response to metronidazole (50% failure rate with initial course of treatment) Increasing impact on IBD patients reported McDonald LC et al. Emerg Infect Dis. 2006;12: McDonald LC et al. Emerg Infect Dis. 2006;12: Loo VG et al. N Engl J Med. 2005;353:2442. Year
8 Clostridium difficile and IBD C. difficile and IBD present in identical fashion ranging from mild diarrhea to fulminant colitis Early studies performed 2 decades ago indicated little overlap between C. difficile and IBD. It concluded No need for routine screening for C. difficile in IBD population Recent studies: Increasing incidence and severity of C. difficile in IBD population C. difficile recently identified to have a significant negative impact on IBD morbidity Kochlar R et al. J Clin Gastroenterol. 1993;16: Bolton RP et al. Lancet. 1980;1: Trnka Y et al. Gastroenterology. 1981;80: Issa M et al. Clin Gastroenterol Hepatol. 2007; Rodemann JF et al. Clin Gastroenterol Hepatol. 2007; 5: Ananthakrishnan A et al. Gut. 2008;57:
9 Cases/1000 admissions Increasing Impact of C difficile on IBD UC** IBD CD* Non-IBD* Year Rodemann JF et al. Clin Gastroenterol Hepatol. 2007;5: Meyer AM et al. J Clin Gastroenterol. 2004;38(9): 772-5
10 Number of Patients Complications: C. difficile-infected Patients With IBD* Number of Patients Hospitalizations Colectomies % % # of Patients With IBD With C. diff # of Colectomies *Preliminary data. Issa M et al. Clin Gastroenterol Hepatol. 2007;5:
11 Clostridium difficile in IBD: Morbidity and Mortality Proportion of C. difficile Associated Hospitalizations IBD patients with C. difficile compared with IBD alone: Longer hospital stay Increased hospitalization costs Higher colectomy rates Increased mortality rate 118 IBD C. diff deaths in NIS 2004 (>500 IBD C. diff deaths in U.S. 2004) UC IBD CD Year Ananthakrishnan A, et al. Gut. 2008;57:
12 Clostridium difficile in IBD: Increasing U.S. Hospitalizations Proportion C difficile (per 1000 Hospitalizations) IBD Crohn s UC All patients Year Ananthakrishnan AN et al. Med Clin N Am
13 Number of Cases Decreasing Colectomy Rate Among Hospitalized IBD Patients with C. difficile Number of infections and rate of hospitalization remained constant, but significant decrease in colectomy rate High index of suspicion Use of oral vancomycin superiority over metronidazole Decreased corticosteroid dosing % 45% 40% 35% 30% 25% 20% 15% 10% 5% 0% 45.50% 26% Colectomy rate 3.50% Issa M et al. Clin Gastroenterol Hepatol. 2007;5:
14 C. difficile and IBD: Summary Clostridium difficile and IBD Patients with colitis are at increased risk Maintenance immunosuppression correlated with infection (purine analogs, methotrexate) 10% of cases were new IBD presentations Contributes to flare in setting of new and longstanding disease in remission Recommend multiple stool samples for ELISA toxin A, B analysis. 54% of patients detected on first stool sample No prompt response to metronidazole, consider vancomycin p.o. Issa M et al. Clin Gastroenterol Hepatol. 2007;5:
15 Hypersensitivity Reactions to IBD Therapy: 5ASA Hypersensitivity 5ASA hypersensitivity - bloody diarrhea and abdominal pain in 4% of patients 5ASA hypersensitivity is partially treated with corticosteroids Diagnostic trial - 5ASA holiday Discontinuation of 5ASA in hospitalized IBD patients IBD polypharmacy is common. Mean number of daily medications for Crohn s disease = 6 Schroeder K, et al. N Engl J Med. 1987;317: Sninsky C, et al. Ann Internal Med. 1991;115: Hanauer, et al. Ann Internal Med. 1996;124: Cross RK, et al. Aliment Pharm Therapeutics 2005
16 Percent of Patients Reasons for Medication Nonadherence in UC Forgetful Careless Felt Better Felt Worse Reason for Nonadherence Sewitch MJ, Abrahamowicz M, Barkun A, et al. Am J Gastroenterol 2003
17 Rates of Early Adverse Reactions in Patients with Autoimmune Hepatitis and Crohn s Disease p = % AUTOIMMUNE HEPATITIS 29% CROHN S DISEASE Adverse Reactions No Adverse Reaction 10% Severe adverse reaction to azathioprine/6mp: Fevers, headache, pancreatitis, respiratory failure, blistering skin lesions Within 4 weeks of initiation JS Bajaj et al. Am J Gastroenterol 2005; 100:
18 Recommendation for Colectomy Absolute indications for surgery Exsanguinating hemorrhage Frank perforation Documented or strongly suspected carcinoma Other indications for surgery Severe colitis or toxic megacolon unresponsive to maximal intravenous medical therapy Less severe, but medically intractable symptoms or intolerable medication side effects Kornbluth, A, et al. Am J Gastroenterol. 2004;99(7): c
19 Can we Predict who is at Risk for Colectomy in UC? Proportion without Colectomy Risk of colectomy and history of medical hospitalization for UC (n=246; 103 hospitalized) Duration of Disease (in years) Not hospitalized Hospitalized Ananthakrishnan AN, McGinley EM, Binion DG. Inflamm Bowel Dis 2009; 15:
20 Crohn s Disease - Medical Management Algorithm: No Partial Obstruction or Abscess Detected Mild Moderate Severe 5-ASA, Budesonide or antibiotics Corticosteroid taper AZA/6MP/MTX to induce/ maintain remission No unable to taper Corticosteroids Yes Inadequate response to AZA/6MP/MTX breakthrough AZA/6MP/MTX maintenance Surgical patients infliximab adalimumab certolizumab natalizumab
21 CD: 20% Present with Surgical Disease Obstruction is an End-Stage Complication Probability (%) Percent of Patients (%)* Mean ± 2 SD Mekhjian HS et al. Gastroenterology. 1979;77: *Kaplan-Meier analysis Years After Onset 0 0 D Years Number of events Munkholm P et al. Gastroenterology. 1993;105:
22 Cumulative Probability (%) Long-Term Course of Crohn s Disease Probability of remaining free of complications Penetrating Surgical patients Complications of CD inflammation Stricturing Months N = 2002 patients with Crohn s disease since diagnosis of the disease Cosnes J et al. Inflamm Bowel Dis. 2002;8:
23 Types of Crohn s Disease Strictures Long stricture Web strictures
24 Ileal CD Web Stricture Intra-Operative Enteroscopy, and Retained M2A Capsule Endoscope Ileal web stricture
25 Search for Occult Strictures Intra-Operative Intraluminal Balloon Sizing Otterson et al, Surgery, 136:854-60, 2004.
26 Crohn s Disease Strictureplasty
27 Small Bowel Crohn s Disease: How Many Strictures? Neo-terminal Ileum stricture 4 upstream strictures detected by intraluminal balloon sizing
28 Accuracy of CD Barium Radiography CD pts 230 strictures by x-ray strictures by intra-op balloon - 36% of patients had x-ray/surgery discrepancy Single Stricture Correct 52% Single Stricture Incorrect 6% Mutiple Strictures Correct 12% Multiple Strictures Incorrect 30% Otterson et al, Surgery, 136:854-60, 2004.
29 Reduced Identification of Strictures Amenable to Strictureplasty Resection Strictureplasty* Over-estimate Accurate Under-estimate * P<0.05 Otterson et al, Surgery, 136:854-60, 2004.
30 Crohn s Disease - Medical Management Algorithm: No Partial Obstruction or Abscess Detected Mild Moderate Severe 5-ASA, Budesonide or antibiotics Corticosteroid taper AZA/6MP/MTX to induce/ maintain remission No unable to taper Corticosteroids Yes Inadequate response to AZA/6MP/MTX breakthrough AZA/6MP/MTX maintenance Surgical patients infliximab adalimumab certolizumab natalizumab
31 Crohn s Disease: 1960 s Historical Perspective Limited treatment: Sulfasalazine, prednisone. No treatment algorithm, limited options available. Irreversible complications.
32 Early disease Inflammation Time Late disease Tissue remodeling
33 Summary and Conclusions - I Acute/severe UC is common Strong suspicion for C.difficile at present time Deterioration with new 5ASA or purine analog consider hypersensitivity adverse reaction Infliximab in outpatient or early inpatient setting
34 Summary and Conclusions - II Occult strictures are found in 1/3 of small bowel CD patients undergoing surgery Post-operative immunodulator/biologic therapy should be considered in CD patients with severe disease (rapid abdominal reoperation cohort) Personalized medicine minimal effective therapy to control inflammation, including postoperative disease
Latest Treatment Updates for Crohn s Disease: Tailoring Therapy David G. Binion, M.D.
Latest Treatment Updates for Crohn s Disease: Tailoring Therapy David G. Binion, M.D. Co-Director, IBD Center Director, Nutrition Support Service UPMC Presbyterian Hospital Division of Gastroenterology,
Speaker Introduction
Speaker Introduction Stephen B. Hanauer, MD Professor of Medicine and Clinical Pharmacology University of Chicago Pritzker School of Medicine Chief of Gastroenterology, Hepatology, and Nutrition University
Ali Keshavarzian MD Rush University Medical Center
Treatment: Step Up or Top Down? Ali Keshavarzian MD Rush University Medical Center Questions What medication should IBD be treated with? Can we predict which patients with IBD are high risk? Is starting
Predicting the natural history of IBD. Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium
Predicting the natural history of IBD Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium Patient 1 Patient 2 Age 22 Frequent cramps and diarrhea for 6 months Weight
CCFA. Crohns Disease vs UC: What is the best treatment for me? November
CCFA Crohns Disease vs UC: What is the best treatment for me? November 8 2009 Ellen J. Scherl,, MD, FACP,AGAF Roberts Inflammatory Bowel Disease Center Weill Medical College Cornell University New York
Treatment Goals. Current Therapeutic Pyramids Crohn s Disease Ulcerative Colitis 11/14/10
Current Management of IBD: From Conventional Agents to Biologics Stephen B. Hanauer, M.D. University of Chicago Treatment Goals Induce and maintain response/ remission Prevent complications Improve quality
Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy
Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy Stephen B. Hanauer, MD University of Chicago Potential Conflicts: Centocor/Schering, Abbott, UCB, Elan, Berlex, PDL Goals of Treatment
12/14/2009. Diagnostic considerations: C. difficile in IBD
Diagnosis and treatment of Gastrointestinal Tract Infections in IBD Case Studies Leonard Baidoo,MD David Binion,MD University of Pittsburgh Medical Center Pittsburgh, Pennsylvania Case 1 46yr old man,1
Management of the Hospitalized IBD Patient. Drew DuPont MD
Management of the Hospitalized IBD Patient Drew DuPont MD Ulcerative Colitis: Indications for Admission Severe ulcerative colitis Frequent loose bloody stools ( 6 per day) Severe cramps Systemic toxicity:
Efficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Assistant Professor of Clinical Pediatrics Division of Gastroenterology,
Disclosures. What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists
What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists Disclosures No financial relationships to disclose. 1 Learning Objectives Case 24M with ileocolonic
11/14/10. A Modern Plague: Clostridium difficile and Inflammatory Bowel Disease
A Modern Plague: Clostridium difficile and Inflammatory Bowel Disease David G. Binion, M.D. Co-Director, Inflammatory Bowel Disease Center Director, Translational Inflammatory Bowel Disease Research Division
Moderately to severely active ulcerative colitis
Adalimumab in the Treatment of Moderate-to-Severe Ulcerative Colitis: ULTRA 2 Trial Results Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients
An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease. David A. Schwartz, MD
An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University
Positioning Biologics in Ulcerative Colitis
Positioning Biologics in Ulcerative Colitis Bruce E. Sands, MD, MS Acting Chief, Gastrointestinal Unit Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Sequential Therapies
Efficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,
Medical Therapy for Pediatric IBD: Efficacy and Safety
Medical Therapy for Pediatric IBD: Efficacy and Safety Betsy Maxwell, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Pediatric IBD: Defining Remission
Beyond Anti TNFs: positioning of other biologics for Crohn s disease. Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center
Beyond Anti TNFs: positioning of other biologics for Crohn s disease Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center Objectives: To define high and low risk patient and disease features
Choosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball
Choosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball Siddharth Singh, MD, MS Assistant Professor of Medicine Division of Gastroenterology Division of Biomedical
Indications for use of Infliximab
Indications for use of Infliximab Moscow, June 10 th 2006 Prof. Dr. Dr. Gerhard Rogler Klinik und Poliklinik für Innere Medizin I Universität Regensburg Case report 1989: Diagnosis of Crohn s disease of
September 12, 2015 Millie D. Long MD, MPH, FACG
Update on Biologic Therapy in 2015 September 12, 2015 Millie D. Long MD, MPH, FACG Assistant Professor of Medicine Inflammatory Bowel Disease Center University of North Carolina-Chapel Hill Outline Crohn
Understanding Inflammatory Bowel Diseases (IBD):
Understanding Inflammatory Bowel Diseases (IBD): What Every Patient Needs to Know William H Holderman, MD Digestive Health Specialists Tacoma, WA Today s Objectives Define IBD, its potential causes and
IBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants
IBD Understanding Your Medications Thomas V. Aguirre, MD Santa Barbara GI Consultants IBD Understanding Your Medications (& Your Doctor) Thomas V. Aguirre, MD Santa Barbara GI Consultants Disclosure I
Crohn s Disease: A New Approach to an Old Problem
Management of Postoperative Crohn s Disease: A New Approach to an Old Problem Miguel Regueiro, M.D. Associate Professor of Medicine Associate Chief for Education Clinical Head and Co-Director, IBD Center
-2002: Rectal blood loss, UC? (no definite diagnosis) rectal mesalazine. -June 2008: Recurrence of rectal blood loss and urgency
SD, male 40 yrs. old. (680718M467.) -2002: Rectal blood loss, UC? (no definite diagnosis) rectal mesalazine -June 2008: Recurrence of rectal blood loss and urgency Total colonoscopy: ulcerative rectitis,
Best Practices in the Diagnosis and Treatment of Inflammatory Bowel Disease
Best Practices in the Diagnosis and Treatment of Inflammatory Bowel Disease Mark Lazarev, MD Summary Inflammatory bowel disease (IBD) is a complex disease that is costly both in terms of medical costs
NEW INSIGHTS INTO THE DIAGNOSIS AND TREATMENT OF REFRACTORY IBD, DAVID GEORGE BINION, MD 1
IBD, DAVID GEORGE BINION, MD 1 So I was asked to present on a topic that I think is a better topic for a full symposium, so a two day symposium, which is the approach to the very, very sick patient with
Recent Advances in the Management of Refractory IBD
Recent Advances in the Management of Refractory IBD Raina Shivashankar, M.D. Assistant Professor of Medicine Division of Gastroenterology and Hepatology Thomas Jefferson University Philadelphia, PA Outline
My Child Has Inflammatory Bowel Disease : Why? What now? What s next?
My Child Has Inflammatory Bowel Disease : Why? What now? What s next? George M. Zacur, M.D., M.S. Clinical Assistant Professor Department of Pediatrics and Communicable Diseases Division of Gastroenterology
Ulcerative Colitis: State of the Art 2006
Ulcerative Colitis: State of the Art David T. Rubin, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center University of Chicago Improving Management of Ulcerative Colitis (UC) Better classification/diagnostic
TREATMENT OF INPATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS
TREATMENT OF INPATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS Target Audience: Physicians, Physician Assistants, Nurse Practitioners and Nurses impacted by the protocol. Scope/Patient Population: All adult
TREATMENT OF INPATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS
TREATMENT OF INPATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS Target Audience: Physicians, Physician Assistants, Nurse Practitioners and Nurses impacted by the protocol. Scope/Patient Population: All adult
Personalized Medicine in IBD
Personalized Medicine in IBD Anita Afzali MD, MPH Assistant Professor of Medicine Director, Inflammatory Bowel Diseases Program University of Washington Harborview Medical Center CCFA April 2 nd, 2016
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 October 2012 REMICADE 100 mg, powder for concentrate for solution for infusion B/1 vial (CIP code: 562 070-1) Applicant:
Crohn s Disease. Resident Lecture 1/17/19
Crohn s Disease Resident Lecture 1/17/19 Objectives Features/Classification of Crohn s Disease Medical Treatment Surgical Indications Surgical Considerations 2 Case 25 yo F presents to your office with
Immunogenicity of Biologic Agents and How to Prevent Sensitization
Immunogenicity of Biologic Agents and How to Prevent Sensitization William J. Sandborn, MD Professor and Chief, Division of Gastroenterology Director, UCSD IBD Center La Jolla, California, USA Learning
Ileal Pouch Anal Anastomosis: The Preferred Method of Reconstruction after Proctocolectomy in Children
Ileal Pouch Anal Anastomosis: The Preferred Method of Reconstruction after Proctocolectomy in Children Stephanie Jones, D.O. Surgical Fellow March 21, 2011 Ulcerative Colitis Spectrum of inflammatory bowel
Treatment of Inflammatory Bowel Disease. Michael Weiss MD, FACG
Treatment of Inflammatory Bowel Disease Michael Weiss MD, FACG What is IBD? IBD is an immune-mediated chronic intestinal disorder, characterized by chronic or relapsing inflammation within the GI tract.
How to Optimize Induction and Maintenance Responses: Definitions and Dosing Advances in Inflammatory Bowel Disease December 6, 2009
How to Optimize Induction and Maintenance Responses: Definitions and Dosing 2009 Advances in Inflammatory Bowel Disease December 6, 2009 Fernando Velayos MD MPH University of California, San Francisco
Common Questions in Crohn s Disease Therapy. Case
Common Questions in Crohn s Disease Therapy Jean-Paul Achkar, MD, FACG Kenneth Rainin Chair for IBD Research Cleveland Clinic Case 23 yo male with 1 year history of diarrhea, abdominal pain and 15 pound
INFLIXIMAB FOR PREVENTION OF POST-OPERATIVE CROHN S DISEASE RECURRENCE: THE PREVENT TRIAL
INFLIXIMAB FOR PREVENTION OF POST-OPERATIVE CROHN S DISEASE RECURRENCE: THE PREVENT TRIAL A. Hillary Steinhart, MD MSc FRCP(C) Medical Lead, Mount Sinai Hospital IBD Centre Professor of Medicine University
Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients
Alimentary Pharmacology and Therapeutics Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients A. B. Mohabbat*, W. J. Sandborn, E. V. Loftus Jr, R. H. Wiesner
How do I choose amongst medicines for inflammatory bowel disease. Maria T. Abreu, MD
How do I choose amongst medicines for inflammatory bowel disease Maria T. Abreu, MD Overview of IBD Pathogenesis Bacterial Products Moderately Acutely Inflamed Chronic Inflammation = IBD Normal Gut Mildly
Crohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Brian Feagan, MD, FACG Professor of Medicine and Epidemiology and Biostatistics Director, Robarts Clinical Trials Robarts Research Institute University
Protocol for the management of acute severe ulcerative colitis in children
Protocol for the management of acute severe ulcerative colitis in children Introduction: Paediatric UC is severe and more extensive than adult onset UC with 6-8% presenting as pancolitis (1,2) Within five
Prevention and Management of Postoperative Crohn s disease
Prevention and Management of Postoperative Crohn s disease Miguel Regueiro, M.D. Associate Professor of Medicine Associate Chief for Education Clinical Head and Co-Director, IBD Center Director, Gastroenterology,
5-ASA Therapy, Steroids and Antibiotics in Inflammatory Bowel Disease
5-ASA Therapy, Steroids and Antibiotics in Inflammatory Bowel Disease David T. Rubin, MD Associate Professor of Medicine Co-Director, Inflammatory Bowel Disease Center University it of Chicago Medical
Stony Brook Adult Clostridium difficile Management Guidelines. Discontinue all unnecessary antibiotics
Stony Brook Adult Clostridium difficile Management Guidelines Summary: Use of the C Diff Infection (CDI) PowerPlan (Adult) Required Patient with clinical findings suggestive of Clostridium difficile infection
IBD Updates. Themes in IBD IBD management journey. New tools for therapeutic monitoring. First-line treatment in IBD
IBD Updates Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida Themes in IBD 213 First-line treatment in IBD New tools for therapeutic monitoring Biologic therapy for CD and
Initiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease
Initiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease The Case for Starting with Anti-TNFα Agents Maria Oliva-Hemker, M.D. Chief, Division of Pediatric Gastroenterology &
Azathioprine for Induction and Maintenance of Remission in Crohn s Disease
Azathioprine for Induction and Maintenance of Remission in Crohn s Disease William J. Sandborn, MD Chief, Division of Gastroenterology Director, UCSD IBD Center Objectives Azathioprine as induction and
Impact of Clostridium difficile infection in patients with ulcerative colitis
Journal of Crohn's and Colitis (2011) 5, 34 40 available at www.sciencedirect.com Impact of Clostridium difficile infection in patients with ulcerative colitis Revital Kariv, Udayakumar Navaneethan, Preethi
Diarrhoea for the Acute Physician
Diarrhoea for the Acute Physician STEPHEN INNS GASTROENTEROLOGIST AND PHYSICIAN HUTT VALLEY DHB August 2013 Outline Case History 1 Initial assessment of acute diarrhoea Management of fulminant UC Management
5/2/2018 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD
5/2/218 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD Grant support for preclinical studies: Janssen, Gusto Global, Vedanta, Artizan BALFOUR SARTOR, MD DISTINGUISHED
Biologics in IBD. Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College
Biologics in IBD Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College Case 30 year old man diagnosed with ulcerative proctitis diagnosed in 2003 Had been maintained
Crohn's disease CAUSES COURSE OF CROHN'S DISEASE TREATMENT. Sulfasalazine
Crohn's disease Crohn's disease is an inflammatory condition of the digestive tract that affects children and adults. Common features of Crohn's disease include mouth sores, diarrhea, abdominal pain, weight
Of Treatment For Inflammatory Bowel Diseases
Balancing The Risks And Benefits Of Treatment For Inflammatory Bowel Diseases Corey A. Siegel, MD Assistant Professor of Medicine Dartmouth Medical School Director, Inflammatory Bowel Diseases Center Dartmouth-Hitchcock
What is Crohn's disease?
What is Crohn's disease? Crohn's disease is a chronic inflammatory disorder that causes inflammation of the digestive tract. It can affect any area of the GI tract, from the mouth to the anus, but it most
Definitions. Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency)
CROHN S DISEASE Definitions Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency) Recurrence: The reappearance of lesions after surgical resection Endoscopic remission:
Surgical Management of IBD. Val Jefford Grand Rounds October 14, 2003
Surgical Management of IBD Val Jefford Grand Rounds October 14, 2003 Introduction Important Features Clinical Presentation Evaluation Medical Treatment Surgical Treatment Cases Overview Introduction Two
Anne Griffiths MD, FRCPC. SickKids Hospital, University of Toronto. Buenos Aires, August 16, 2014
Management and Medical Therapies for Crohn disease: strategies to enhance mucosal healing Anne Griffiths MD, FRCPC SickKids Hospital, University of Toronto Buenos Aires, August 16, 2014 New onset Crohn
INFLAMMATORY BOWEL DISEASE. Jean-Paul Achkar, MD Center for Inflammatory Bowel Disease Cleveland Clinic
INFLAMMATORY BOWEL DISEASE Jean-Paul Achkar, MD Center for Inflammatory Bowel Disease Cleveland Clinic WHAT IS INFLAMMATORY BOWEL DISEASE (IBD)? Chronic inflammation of the intestinal tract Two related
Garrick Brown, MD. Digestive Health Specialists Tacoma Gig Harbor
Garrick Brown, MD Digestive Health Specialists Tacoma Gig Harbor Today s Objectives Define IBD, its potential causes and diagnosis Discuss management and treatment Discuss complementary and alternative
International Journal of Pediatrics and Neonatal Health
Research Article International Journal of Pediatrics and Neonatal Health Open Access Clostridium difficile Infection in Pediatric Inflammatory Bowel Disease Patients in the Era of Molecular Diagnostics
T he treatment strategy for Crohn s disease (CD) is
237 INFLAMMATORY BOWEL DISEASE Impact of the increasing use of immunosuppressants in Crohn s disease on the need for intestinal surgery J Cosnes, I Nion-Larmurier, L Beaugerie, P Afchain, E Tiret, J-P
Severe IBD: What to Do When Anti- TNFs Don t Work?
Severe IBD: What to Do When Anti- TNFs Don t Work? David T. Rubin, MD, FACG Professor of Medicine Co-Director, Inflammatory Bowel Disease Center Interim Chief, Section of Gastroenterology, Hepatology and
Index. Surg Clin N Am 87 (2007) Note: Page numbers of article titles are in boldface type.
Surg Clin N Am 87 (2007) 787 796 Index Note: Page numbers of article titles are in boldface type. A Abscesses in anorectal Crohn s disease, 622 intra-abdominal, in Crohn s disease, 590 591 perirectal,
IBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition
IBD 101 Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Objectives Identify factors involved in the development of inflammatory bowel
Patho Basic Chronic Inflammatory Bowel Diseases. Jürg Vosbeck Pathology
Patho Basic Chronic Inflammatory Bowel Diseases Jürg Vosbeck Pathology General Group of chronic relapsing diseases with chronic bloody or watery diarrhea Usually ulcerative colitis (UC) or Crohn s disease
The role of Surgery and Stomas in IBD
The role of Surgery and Stomas in IBD When do I need it? Can I avoid it? How do I live with it? Kyle G. Cologne, MD Assistant Professor of Surgery USC Division of Colorectal Surgery Topics Surgical Differences
To help protect your privacy, PowerPoint prevented this external picture from being automatically downloaded. To download and display this picture,
To help protect your privacy, PowerPoint prevented this external picture from being automatically downloaded. To download and display this picture, click Options in the Message Bar, and then click Enable
Latest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals
Latest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker
Addressing Risks and Benefits In IBD
Addressing Risks and Benefits In IBD Gil Y. Melmed, MD, MS Assistant Professor of Medicine, Cedars-Sinai Medical Center David Geffen School of Medicine at UCLA www.nomorecrohnsdisease.com "Jaw Dropping
Clostridium difficile associated diarrhea (CDAD) has emerged. Incidence of Clostridium difficile Infection in Inflammatory Bowel Disease
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2007;5:339 344 Incidence of Clostridium difficile Infection in Inflammatory Bowel Disease JOSEPH F. RODEMANN,* ERIK R. DUBBERKE, KIMBERLY A. RESKE, DA HEA SEO,*
PEDIATRIC INFLAMMATORY BOWEL DISEASE
PEDIATRIC INFLAMMATORY BOWEL DISEASE Alexis Rodriguez, MD Pediatric Gastroenterology Advocate Children s Hospital Disclosers Abbott Nutrition - Speaker Inflammatory Bowel Disease Chronic inflammatory disease
Guided by Dr. Michal Amitai Head of Abdominal Imaging Department of Diagnostic Imaging Sheba Medical Center Sackler School of Medicine, Tel Aviv
Guided by Dr. Michal Amitai Head of Abdominal Imaging Department of Diagnostic Imaging Sheba Medical Center Sackler School of Medicine, Tel Aviv University 1 SHARE study My year Collaboration between gastroenterology
Gary R. Lichtenstein, MD, FACG
Symposium B: Clinical Challenges in IBD A Case-based Approach refractory ibd Gary R. Lichtenstein, MD, FACG Key Take Home Points Establish the correct extent, type of IBD (UC versus CD) and establish disease
Selby Inflamm Bowel Dis. 2008:14:
Medical Management of Inflammatory Bowel Disease Freddy Caldera D.O. Assistant Professor Division of Gastroenterology Objectives Discuss Crohn s disease and Ulcerative Colitis Discuss Medications for Inflammatory
Perianal and Fistulizing Crohn s Disease: Tough Management Decisions. Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic
Perianal and Fistulizing Crohn s Disease: Tough Management Decisions Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic Talk Overview Background Assessment and Classification
I B D. etter than this. isease UNDERSTANDING INFLAMMATORY BOWEL DISEASES
I B D m etter than this isease UNDERSTANDING INFLAMMATORY BOWEL DISEASES What types of people have learned how to manage their IBD? Athletes Musicians Firefighters DOCTORS HEROES Artists Presidents Actors
P a g e 1. Inflammatory Bowel Disease Guidelines
P a g e 1 Inflammatory Bowel Disease Guidelines Introduction Inflammatory bowel disease (IBD) is a chronic inflammatory disease affecting the gastrointestinal (GI) system. It is comprised of two major
Agenda. Predictive markers in IBD. Management of ulcerative colitis. Management of Crohn s disease
Agenda Predictive markers in IBD Management of ulcerative colitis Management of Crohn s disease 2 Patients With UC (%) Distribution of UC Disease Severity at Presentation 1 Fulminant disease (9%) 8 6 4
Management of Clostridium Difficile: Total Colectomy versus Colon Sparing Surgery
Management of Clostridium Difficile: Total Colectomy versus Colon Sparing Surgery Rahul Narang, MD Colon and Rectal Surgery Assistant Professor of Surgery No Disclosure Clostridium Difficile Colitis: Treatments,
Surgery and Stomas in IBD When do I need it? Can I avoid it? How do I live with it?
Surgery and Stomas in IBD When do I need it? Can I avoid it? How do I live with it? Kyle G. Cologne, MD Assistant Professor of Surgery USC Division of Colorectal Surgery Topics Surgical Differences between
Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease
Aliment Pharmacol Ther 23; 18 (Suppl. 2): 1 5. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease P. MUNKHOLM Department of Medical Gastroenterology, Hvidovre
Spectrum of Diverticular Disease. Outline
Spectrum of Disease ACG Postgraduate Course January 24, 2015 Lisa Strate, MD, MPH Associate Professor of Medicine University of Washington, Seattle, WA Outline Traditional theories and updated perspectives
... Inflammatory disorder of the colon that occurs as a complication of antibiotic treatment.
Definition Inflammatory disorder of the colon that occurs as a complication of antibiotic treatment. " Epidemiology Humans represent the main reservoir of Clostridium difficile, which is not part of the
The Spectrum of IBD. Inflammatory Bowel Disease. Symptoms. Epidemiology. Tests for IBD. CD or UC? Inflamatory Bowel Disease. Fernando Vega, M.D.
The Spectrum of IBD Inflammatory Bowel Disease Fernando Vega, M.D. Epidemiology CD and UC together 1:400 UC Prevalence 1:500 UC Incidence 6-12K/annum CD Prevalence 1:1000 CD Incidence 3-6K/annum Symptoms
Surgical Management of IBD in the Age of Biologics
Surgical Management of IBD in the Age of Biologics Lisa S. Poritz, M.D Associate Professor of Surgery Division of Colon and Rectal Surgery Objectives Discuss surgical management of IBD When to operate
Welcome to Week 2 of the Crohn s & Colitis Foundation of America (CCFA) Online Support Group.
Welcome to Week 2 of the Crohn s & Colitis Foundation of America (CCFA) Online. Last week s material consisted of an overview of inflammatory bowel diseases (IBD), specifically Crohn s disease and ulcerative
The Best of IBD at UEGW (Crohn s)
The Best of IBD at UEGW (Crohn s) Iyad Issa MD Head of Gastroenterology, Rafik Hariri Univ Hosp Adjunct Faculty, School of Medicine, Leb Univ Founding Faculty, School Of Medicine, Leb Am Univ 1 The Best
Ulcerative Colitis Therapy. Faculty Disclosure. Acknowledgements 28/11/2013. Amy Morse November 30/13
Ulcerative Colitis Therapy Amy Morse November 30/13 GI for GP s Jasper AB Faculty Disclosure Faculty: Amy Morse Relationships with commercial interests: Grants/Research Support: Therapeutic Fellowship
Join the conversation at #GIFORUMCCFA
1 Join the conversation at #GIFORUMCCFA 2 Disclosures In accordance with the ACCME Standards for Commercial Support of CME, the speakers for this course have been asked to disclose to participants the
DENOMINATOR: All patients aged 18 and older with a diagnosis of inflammatory bowel disease
Measure #270: Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Sparing Therapy National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY
CLINICAL MEDICAL POLICY
Policy Name: Policy Number: Responsible Department(s): CLINICAL MEDICAL POLICY Tysabri (natalizumab) MP-042-MD-WV Provider Notice Date: 10/01/2017 Original Effective Date: 11/01/2017 Annual Approval Date:
INFLAMMATORY BOWEL DISEASE
1. Medical Condition INFLAMMATORY BOWEL DISEASE (IBD) specifically includes Crohn s disease (CD) and ulcerative colitis (UC) but also includes IBD unclassified (IBDu), seen in about 10% of cases. These
Crohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Gary R. Lichtenstein, MD, FACG Professor of Medicine Director, Inflammatory Bowel Disease Program University of Pennsylvania Philadelphia, PA In my
Clostridium difficile Infection (CDI) Management Guideline
Clostridium difficile Infection (CDI) Management Guideline Do not test all patients with loose or watery stools for CDI o CDI is responsible for
Treating Crohn s and Colitis in the ASC
Treating Crohn s and Colitis in the ASC Kimberly M Persley, MD Texas Digestive Disease consultants TASC Meeting Outline IBD 101 Diagnosis Treatment Burden of Disease Role of ASC Inflammatory Bowel Disease
Clinical guideline Published: 10 October 2012 nice.org.uk/guidance/cg152
Crohn's disease: management Clinical guideline Published: 10 October 2012 nice.org.uk/guidance/cg152 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).